BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I

Having validated its vaccine platform in Covid-19, Expres2ion Biotech now turns to the treatment of breast cancer. A SEK 60 million rights issue of units will fund a phase I study with the breast cancer vaccine candidate ES2B-C001, building on promising preclinical results. The capital raise will also support the cytomegalovirus vaccine discovery project in the Evaxion collaboration, and other working capital including in the grant sponsored research and development.

Read the full article at biostock.se:

https://www.biostock.se/2024/06/rights-issue-takes-expres2ion-breast-cancer-vaccine-to-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se